JPH10511689A - アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤の毒性を減少させる方法 - Google Patents
アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤の毒性を減少させる方法Info
- Publication number
- JPH10511689A JPH10511689A JP9502184A JP50218497A JPH10511689A JP H10511689 A JPH10511689 A JP H10511689A JP 9502184 A JP9502184 A JP 9502184A JP 50218497 A JP50218497 A JP 50218497A JP H10511689 A JPH10511689 A JP H10511689A
- Authority
- JP
- Japan
- Prior art keywords
- uridine
- administering
- acyl derivative
- derivative
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)通常の最大耐容用量の少なくとも1.5倍を越える用量のピリミジンヌ クレオシド類似体を投与する工程、そして (b)非メチル化ピリミジンヌクレオシドのアシル誘導体の薬学的に有効な量を 投与する工程、 を包含する、癌を処置する方法。 2.前記ピリミジンヌクレオシド類似体が、5-フルオロウラシル(5-FU)、テガ フールおよび5'-デオキシフルオロウリジンを含む5FUプロドラッグ、フルオロウ リジン、2'-デオキシフルオロウリジン、フルオロウリジンまたは2'-デオキシフ ルオロウリジンのプロドラッグ誘導体、フルオロシトシン、トリフルオロメチル -2'-デオキシウリジン、アラビノシル、シトシン、アラビノシルシトシンのプロ ドラッグ、シクロシチジン、5-アザ-2'-デオキシシチジン、アラビノシル5-アザ シトシン、6-アザシチジン、N-ホスホノアセチル-L-アスパラギン酸(PALA)、 ピラゾフリン、6-アザウリジン、アザリビン、チミジンおよび3-デアザウリジン からなる群より選択される、請求項1に記載の方法。 3.前記ピリミジンヌクレオシド類似体が、5-フルオロピリミジンまたは5-フル オロピリミジンヌクレオシド類似体であり、前記非メチル化ピリミジンヌクレオ シドのアシル誘導体が、ウリジン、シチジンまたはデオキシウリジンのアシル誘 導体である、請求項1に記載の方法。 4.前記5-フルオロピリミジンまたは5-フルオロピリミジンヌクレオシド類似体 が、5-フルオロウラシル、テガフールおよび5'-デオキシフルオロウリジンを含 む5-フルオロウラシルのプロドラッグ誘導体、フルオロウリジン、2'-デオキシ フルオロウリジン、フルオロウリジンのプロドラッグ誘導体、2'-デオキシフル オロウリジンのプロドラッグ誘導体、5-フルオロシトシン、5-フルオロシチジン 、または5-フルオロシチジンのプロドラッグ誘導体からなる群より選択される、 請 求項3に記載の方法。 5.前記5-フルオロピリミジンまたは5-フルオロピリミジンヌクレオシド類似体 が5-フルオロウラシルである、請求項3に記載の方法。 6.前記投与工程(a)が900〜2400 mg/m2ボーラスの5-フルオロウラシルを投 与する工程を包含し、そして前記投与工程(b)が、工程(a)の2〜24時間後 に、非メチル化ピリミジンヌクレオシドのアシル誘導体1〜10gを投与する工程 を包含し、ここで、工程(a)および(b)が3〜6回繰り返される、請求項5 に記載の方法。 7.前記工程(a)の各反復の間の時間間隔が4〜14日である、請求項6に記載 の方法。 8.前記投与工程(a)が600〜1000 mg/m2ボーラスの5-フルオロウラシルを4 〜5日間連続で毎日投与する工程を包含し、そして前記投与工程(b)が、各工 程(a)の各2〜12時間後に、非メチル化ピリミジンヌクレオシドのアシル誘導 体1〜10gを投与する工程を包含する、請求項5に記載の方法。 9.前記ピリミジンヌクレオシド類似体が、N-ホスホノアセチル-L-アスパラギ ン酸(PALA)、ピラゾフリン、6-アザウリジン、アザリビン、トリフルオロメチ ル-2'-デオキシウリジンまたは3-デアザウリジンであり、そして前記非メチル化 ピリミジンヌクレオシドのアシル誘導体が、ウリジンまたはシチジンのアシル誘 導体である、請求項1に記載の方法。 10.前記非メチル化ピリミジンヌクレオシドのアシル誘導体がウリジン、シチ ジン、デオキシシチジンまたはデオキシウリジンのアシル誘導体である、請求項 1に記載の方法。 11.前記非メチル化ピリミジンヌクレオシドのアシル誘導体が、トリアセチル ウリジンである、請求項1に記載の方法。 12.前記非メチル化ピリミジンヌクレオシドのアシル誘導体が、エトキシカル ボニルウリジンである、請求項1に記載の方法。 13.前記非メチル化ピリミジンヌクレオシドのアシル誘導体が、トリアセチル シチジンである、請求項1に記載の方法。 14.前記非メチル化ピリミジンヌクレオシドのアシル誘導体が、ジアセチルデ オキシシチジンである、請求項1に記載の方法。 15.前記ピリミジンヌクレオシド類似体が、シチジンの抗腫瘍性類似体であり 、そして前記非メチル化ピリミジンヌクレオシドのアシル誘導体が、デオキシシ チジンのアシル誘導体である、請求項1に記載の方法。 16.前記シチジンの抗腫瘍性類似体が、アラビノシルシトシンまたはそのプロ ドラッグ、シクロシチジン、5-アザ-2'-デオキシシチジン、アラビノシル5-アザ シトシン、または6-アザシチジンである、請求項15に記載の方法。 17.前記ピリミジンヌクレオシド類似体がウリジン類似体であり、前記非メチ ル化ピリミジンヌクレオシドのアシル誘導体が、ウリジン、デオキシウリジンま たはシチジンのアシル誘導体であり、そして前記投与工程(b)がまた、ウリジ ンホスホリラーゼの阻害剤を投与する工程を包含する、請求項1に記載の方法。 18.前記ウリジンホスホリラーゼの阻害剤が、ベンジルアシクロウリジン、ベ ンジルオキシベンジルアシクロウリジン、アミノメチル-ベンジル-アシクロウリ ジン、アミノメチルベンジルオキシベンジルアシクロウリジン、ヒドロキシメチ ルベンジルアシクロウリジン、ヒドロキシメチル-ベンジルオキシベンジルアシ クロウリジン、2,2'-アンヒドロ-5-エチルウリジン、5-ベンジルバルビツール塩 、5-ベンジルオキシベンジルバルビツール塩、5-ベンジルオキシベンジル-1-[(1 -ヒドロキシ-2-エトキシ)メチル]バルビツール塩、5-ベンジルオキシベンジルア セチル-1-[(1-ヒドロキシ-2-エトキシ)メチル]バルビツール塩および5-メトキシ ベンジルアセチルアシクロバルビツール塩からなる群より選択される、請求項1 7に記載の方法。 19.前記非メチル化ピリミジンヌクレオシドのアシル誘導体が、シチジンまた はデオキシシチジンのアシル誘導体であり、そして前記投与工程(b)がまた、 シチジンデアミナーゼの阻害剤を投与する工程を包含する、請求項1に記載の方 法。 20.前記シチジンデアミナーゼの阻害剤が、テトラヒドロウリジンまたばテト ラヒドロ-2'-デオキシウリジンからなる群より選択される、請求項19に記載の 方法。 21.前記非メチル化ピリミジンヌクレオシドのアシル誘導体が、ウリジン、シ チジンまたはデオキシシチジンのアシル誘導体であり、そして前記投与工程(b )がまた、ヌクレオシド輸送の阻害剤を投与する工程を包含する、請求項1に記 載の方法。 22.前記ヌクレオシド輸送の阻害剤が、ジラゼプ、ジピリダモール、プロベニ シド、リドフラジンまたはニトロベンジルチオイノシンからなる群より選択され る、請求項21に記載の方法。 23.前記投与工程(b)がまた、造血を強化する薬剤を投与する工程を包含す る、請求項1に記載の方法。 24.前記投与工程(b)がまた、細胞内へのヌクレオシドの吸収とリン酸化を 高める得る化合物を投与する工程を包含する、請求項1に記載の方法。 25.前記投与工程(a)がまた、AZTを投与する工程を包含する、請求項1に 記載の方法。 26.前記フッ素化ピリミジンが、5-フルオロウラシル効力の生化学的モジュレ ーターと共に組み合わせて投与される、請求項1に記載の方法。 27.前記モジュレーターが、プリン生合成の阻害剤、葉酸代謝拮抗薬ピリミジ ン生合成の阻害剤または5-フルオロウラシル分解の阻害剤である、請求項26に 記載の方法。 28.前記プリン生合成の阻害剤が、メチルメルカプトプリンリボシドである、 請求項27に記載の方法。 29.前記葉酸代謝拮抗薬が、メトトレキサートまたはトリメトトレキサートで ある、請求項27に記載の方法。 30.前記ピリミジン生合成の阻害剤が、PALA、ブレキナル、アシビシンまたは 6-アザウリジンである、請求項27に記載の方法。 31.前記5-フルオロウラシル分解の阻害剤が、酵素ジヒドロピリミジンデヒド ロゲナーゼの阻害剤である、請求項27に記載の方法。 32.前記ジヒドロピリミジンデヒドロゲナーゼの阻害剤が、5-エチニルウラシ ル、ブロモビニルウラシル、CDHP、ウラシル、チミン、チミジンまたはベンジル オキシベンジルウラシルである、請求項31に記載の方法。 33.(a)前記酵素ジヒドロピリミジンデヒドロゲナーゼの阻害剤を投与する 工程; (b)5-フルオロピリミジンまたは5-フルオロピリミジンヌクレオシド類似体を 投与する工程; (c)非メチル化ピリミジンヌクレオシドのアシル誘導体を薬学的有効量で投与 する工程、 を包含する、癌を処置する方法。 34.前記5-フルオロピリミジンまたは5-フルオロピリミジンヌクレオシド類似 体が、5-フルオロウラシル、テガファールおよび5'-デオキシフルオロウリジン を含む5-フルオロウラシルのプロドラッグ、フルオロウリジン、2'-デオキシフ ルオロウリジン、フルオロウリジンのプロドラッグ誘導体、2'-デオキシフルオ ロウリジンのプロドラッグ誘導体、5-フルオロシトシン、5-フルオロシチジン、 または5-フルオロシチジンのプロドラッグ誘導体からなる群より選択される、請 求項33に記載の方法。 35.前記ジヒドロピリミジンデヒドロゲナーゼの阻害剤が、5-エチニルウラシ ル、ブロモビニルウラシル、シアノジヒドロピリジン、ウラシル、チミン、チミ ジンまたはベンジルオキシベンジルウラシルである、請求項33に記載の方法。 36.前記投与工程(a)が、前記投与工程(b)の前または同時に行われる、 請求項33に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/472,210 US5968914A (en) | 1987-10-28 | 1995-06-07 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
US08/472,210 | 1995-06-07 | ||
PCT/US1996/010067 WO1996040165A1 (en) | 1995-06-07 | 1996-06-06 | Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated pyrimidine nucleosides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003000721A Division JP2003201240A (ja) | 1995-06-07 | 2003-01-06 | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤の毒性を減少させる方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10511689A true JPH10511689A (ja) | 1998-11-10 |
Family
ID=23874595
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9502184A Withdrawn JPH10511689A (ja) | 1995-06-07 | 1996-06-06 | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤の毒性を減少させる方法 |
JP2003000721A Withdrawn JP2003201240A (ja) | 1995-06-07 | 2003-01-06 | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤の毒性を減少させる方法 |
JP2009110077A Pending JP2009167213A (ja) | 1995-06-07 | 2009-04-28 | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤の毒性を減少させる方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003000721A Withdrawn JP2003201240A (ja) | 1995-06-07 | 2003-01-06 | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤の毒性を減少させる方法 |
JP2009110077A Pending JP2009167213A (ja) | 1995-06-07 | 2009-04-28 | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤の毒性を減少させる方法 |
Country Status (14)
Country | Link |
---|---|
US (2) | US5968914A (ja) |
EP (2) | EP0831849A4 (ja) |
JP (3) | JPH10511689A (ja) |
KR (1) | KR19990022804A (ja) |
CN (1) | CN1192149A (ja) |
AT (1) | ATE320813T1 (ja) |
AU (1) | AU724805B2 (ja) |
CA (1) | CA2223640A1 (ja) |
DE (1) | DE69635941T2 (ja) |
DK (1) | DK1491201T3 (ja) |
ES (1) | ES2257721T3 (ja) |
HK (1) | HK1072897A1 (ja) |
PT (1) | PT1491201E (ja) |
WO (1) | WO1996040165A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011500713A (ja) * | 2007-10-16 | 2011-01-06 | エイザイ インコーポレイテッド | シチジンデアミナーゼ阻害剤としての2’−フルオロ−2’−デオキシテトラヒドロウリジン |
JP2011513415A (ja) * | 2008-03-03 | 2011-04-28 | トスク インコーポレーティッド | 毒性を低減するためのメトトレキセートアジュバントおよびその使用法 |
US11446303B2 (en) | 2019-06-21 | 2022-09-20 | Tosk, Inc. | Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5691320A (en) * | 1987-10-28 | 1997-11-25 | Pro-Neuron, Inc. | Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis |
US7776838B1 (en) * | 1987-10-28 | 2010-08-17 | Wellstat Therapeutics Corporation | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
CA2213385A1 (en) * | 1997-08-20 | 1999-02-20 | Eng-Hong Lee | Method of protecting against coccidiosis infections in poultry |
AU8388198A (en) * | 1997-08-21 | 1999-03-08 | Basf Aktiengesellschaft | Use of uridine to counter 5-fluorouracil toxicity |
US6136339A (en) * | 1998-08-21 | 2000-10-24 | Gardiner; Paul T. | Food supplements and methods comprising lipoic acid and creatine |
US7807654B2 (en) | 1998-08-31 | 2010-10-05 | Wellstat Therapeutics Corporation | Compositions and methods for treatment of mitochondrial diseases |
US7915233B1 (en) | 1998-08-31 | 2011-03-29 | Wellstat Therapeutics Corporation | Compositions and methods for treatment of mitochondrial diseases |
US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
US7638501B1 (en) | 1999-02-23 | 2009-12-29 | The Regents Of The University Of California | Method of treatment of mitochondrial disorders |
US6875751B2 (en) * | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
AU2001278804A1 (en) * | 2000-08-09 | 2002-02-18 | Kolon Industries, Inc. | 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients |
US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
WO2002069950A2 (en) * | 2001-03-01 | 2002-09-12 | Eli Lilly And Company | Tumor treatement with a combination of a substrate of mrp5 and modulators of mrp5 |
DE10110355A1 (de) * | 2001-03-03 | 2002-09-12 | Ulrich Walker | Bekämpfung von Nebenwirkungen |
US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
US20030082228A1 (en) * | 2001-05-09 | 2003-05-01 | Inex Pharmaceuticals Corporation | Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents |
SE521676C2 (sv) * | 2002-01-02 | 2003-11-25 | Dilafor Ab | Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet |
US20030147813A1 (en) * | 2002-02-07 | 2003-08-07 | John Lyons | Method for treating chronic myelogenous leukemia |
US6998391B2 (en) * | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
EP1352910A1 (en) | 2002-04-10 | 2003-10-15 | Grünenthal GmbH | New analogs of nitrobenzylthioinosine |
US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
CA2503150A1 (en) * | 2002-10-31 | 2004-05-21 | Supergen, Inc. | Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
WO2004104022A2 (en) * | 2003-05-16 | 2004-12-02 | The General Hospital Corporation | Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin a3), inhibitors thereof and methods of use thereof |
US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
US20050059682A1 (en) * | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
PT1750703E (pt) * | 2004-04-29 | 2012-02-23 | Taiho Pharmaceutical Co Ltd | Processo destinado à redução da toxicidade gastrintestinal devida à administração de tegafur |
WO2006009765A2 (en) * | 2004-06-18 | 2006-01-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells |
US20060024376A1 (en) * | 2004-07-30 | 2006-02-02 | The University Of Chicago | Methods and compositions for reducing toxicity associated with leflunomide treatment |
US20080255168A1 (en) * | 2004-12-03 | 2008-10-16 | Adherex Technologies, Inc. | Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs |
US20060128654A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
US7250416B2 (en) * | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
US20070105792A1 (en) * | 2005-11-04 | 2007-05-10 | Dimartino Jorge F | Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases |
US20070117776A1 (en) * | 2005-11-04 | 2007-05-24 | John Lyons | Low Dose Therapy Of DNA Methylation Inhibitors |
US20070269863A1 (en) * | 2005-12-22 | 2007-11-22 | Bridon Dominique P | Process for the production of preformed conjugates of albumin and a therapeutic agent |
AU2007263726A1 (en) | 2006-06-27 | 2008-01-03 | Biovitrum Ab (Publ) | Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists |
NZ573307A (en) | 2006-06-27 | 2012-02-24 | Biovitrum Ab Publ | 2-0'-methyladen0sine derivatives and their use as agonists or antagonists of an adenosine receptor |
EP2240175B1 (en) * | 2008-02-11 | 2013-01-02 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Compounds with mdr1-inverse activity |
US9265785B2 (en) | 2008-12-22 | 2016-02-23 | The Board Of Trustees Of The University Of Illinois | Compositions comprising decitabine and tetrahydrouridine and uses thereof |
US9259469B2 (en) | 2008-12-22 | 2016-02-16 | The Board Of Trustees Of The University Of Illinois | Compositions comprising decitabine and tetrahydrouridine and uses thereof |
TWI477508B (zh) * | 2009-04-06 | 2015-03-21 | Otsuka Pharma Co Ltd | 用以治療癌症之組成物及方法 |
WO2010118013A1 (en) * | 2009-04-06 | 2010-10-14 | Eisai Inc. | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
WO2010118010A1 (en) * | 2009-04-06 | 2010-10-14 | Eisai Inc. | Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
US8617540B2 (en) * | 2009-04-15 | 2013-12-31 | Fox Chase Cancer Center | Combinational chemotherapy treatment |
WO2011007784A1 (ja) | 2009-07-15 | 2011-01-20 | 旭硝子株式会社 | 積層体の製造方法及び積層体 |
EP2348131A1 (en) | 2010-01-22 | 2011-07-27 | Institut Curie | Low levels of cytidine deaminase as a marker for genetic predisposition to develop cancer |
CN102775458B (zh) * | 2011-05-09 | 2015-11-25 | 中国人民解放军军事医学科学院毒物药物研究所 | β-D-(2’R)-2’-脱氧—2’-氟-2’-C-甲基胞苷衍生物的制备及用途 |
AU2012302051B2 (en) | 2011-08-30 | 2017-04-27 | Astex Pharmaceuticals, Inc. | Decitabine derivative formulations |
BR102013022567B1 (pt) * | 2013-09-03 | 2021-09-21 | Uniao Brasileira De Educacão E Assistência | Uso de 6-hidroxi-2-piridonas e seus derivados na preparação de uma composição farmacêutica que atue pela inibição da enzima uridina fosforilase humana |
CN104496972A (zh) * | 2014-12-04 | 2015-04-08 | 浙江大学 | 一种新型替加氟药物共晶及其制备方法 |
EP3303588A4 (en) * | 2015-05-29 | 2019-01-23 | The Board of Trustees of The Leland Stanford Junior University | NUCLEOSIDE AGENTS FOR REDUCING DELULATE GENE ACTIVITY CONTAINING EXTENDED NUCLEOTIDE REPEAT |
RU2723590C2 (ru) | 2015-07-02 | 2020-06-16 | Оцука Фармасьютикал Ко., Лтд. | Лиофилизированные фармацевтические композиции |
WO2018002739A1 (en) * | 2016-06-28 | 2018-01-04 | Cellix Bio Private Limited | Compositions and methods for the treatment of cancer |
AU2018310857A1 (en) | 2017-08-03 | 2020-02-13 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
CN112789048A (zh) * | 2018-08-14 | 2021-05-11 | 托斯克公司 | 用于治疗粘膜炎的方法和组合物 |
CN112770760A (zh) * | 2018-08-14 | 2021-05-07 | 托斯克公司 | 降低辐射诱发的毒性的方法和组合物 |
WO2020226889A1 (en) * | 2019-05-07 | 2020-11-12 | Wellstat Therapeutics Corporation | Formulations of uridine triacetate in triacetin |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
CA3178648A1 (en) * | 2020-05-19 | 2021-11-25 | Mahesh Kandula | Pharmaceutical formulations and their preparations for treatment of cancer |
EP4210709A1 (en) * | 2020-09-14 | 2023-07-19 | Wellstat Therapeutics Corporation | 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position |
WO2022226312A1 (en) * | 2021-04-22 | 2022-10-27 | Clear Creek Bio, Inc. | Combination nucleotide pool depletion for treatment of viral infections and cancers |
CN113336816B (zh) * | 2021-06-03 | 2022-05-17 | 中国医学科学院医药生物技术研究所 | 胞苷类化合物及其抗肿瘤用途 |
CN113332305B (zh) * | 2021-06-03 | 2022-08-16 | 中国医学科学院医药生物技术研究所 | 胞苷类化合物的脂质组合物 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1297398A (ja) * | 1969-08-06 | 1972-11-22 | ||
US4017606A (en) * | 1973-10-04 | 1977-04-12 | The Upjohn Company | Organic compounds and process |
GB1473148A (ja) * | 1974-09-16 | 1977-05-11 | ||
DE3100478A1 (de) * | 1981-01-09 | 1982-08-12 | Dr. Thilo & Co GmbH, 8021 Sauerlach | 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel |
EP0151189B1 (en) * | 1983-07-20 | 1990-01-31 | Teijin Limited | Antineoplastic agent |
JPS60174797A (ja) * | 1984-02-21 | 1985-09-09 | Funai Corp | Ν−アロイルチミジン誘導体ならびに抗腫瘍活性物質の毒性低下剤 |
KR890701609A (ko) * | 1987-10-28 | 1989-12-21 | 원본미기재 | 아실 데옥시리보뉴클레오시드 유도체 및 그의 사용 |
US5736531A (en) * | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
CA1321994C (en) * | 1987-10-28 | 1993-09-07 | Reid Von Borstel | Acylated uridine and cytidine and uses thereof |
US4874602A (en) * | 1988-02-22 | 1989-10-17 | Paul Calabresi | Reduction of the severity 3'-azido-3'-deoxythymidine-induced anemia using benzylacyclouridine |
US5077280A (en) * | 1988-04-12 | 1991-12-31 | Brown University Research Foundation | Treatment of viral infections |
US4950466A (en) * | 1988-06-22 | 1990-08-21 | Paul Calabresi | Reduction of the severity of 3'-azido-3'-deoxythymidine-induced anemia using a combination of benzylacyclouridine and dipyridamole |
JPH03504728A (ja) * | 1989-01-24 | 1991-10-17 | ジェンシア・ファーマシュウティカルズ,インコーポレイテッド | Aicaリボシドの放出および血液グルコースの低減のための化合物および方法 |
US5132291A (en) * | 1989-01-24 | 1992-07-21 | Gensia Pharmaceuticals, Inc. | Antivirals and methods for increasing the antiviral activity of azt |
US5141943A (en) * | 1990-04-12 | 1992-08-25 | Brown University Research Foundation | 5-benzyl barbiturate derivatives |
CA2504078C (en) * | 1991-07-05 | 2007-08-28 | Wellstat Therapeutics Corporation | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
WO1994026761A1 (en) * | 1993-05-14 | 1994-11-24 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
-
1995
- 1995-06-07 US US08/472,210 patent/US5968914A/en not_active Expired - Lifetime
-
1996
- 1996-06-06 EP EP96918461A patent/EP0831849A4/en not_active Ceased
- 1996-06-06 AU AU61114/96A patent/AU724805B2/en not_active Expired
- 1996-06-06 CA CA002223640A patent/CA2223640A1/en not_active Abandoned
- 1996-06-06 PT PT04023557T patent/PT1491201E/pt unknown
- 1996-06-06 KR KR1019970709273A patent/KR19990022804A/ko active Search and Examination
- 1996-06-06 CN CN96195929A patent/CN1192149A/zh active Pending
- 1996-06-06 DE DE69635941T patent/DE69635941T2/de not_active Expired - Lifetime
- 1996-06-06 AT AT04023557T patent/ATE320813T1/de active
- 1996-06-06 ES ES04023557T patent/ES2257721T3/es not_active Expired - Lifetime
- 1996-06-06 EP EP04023557A patent/EP1491201B1/en not_active Expired - Lifetime
- 1996-06-06 DK DK04023557T patent/DK1491201T3/da active
- 1996-06-06 WO PCT/US1996/010067 patent/WO1996040165A1/en not_active Application Discontinuation
- 1996-06-06 JP JP9502184A patent/JPH10511689A/ja not_active Withdrawn
-
1998
- 1998-10-03 HK HK05105421A patent/HK1072897A1/xx not_active IP Right Cessation
-
1999
- 1999-02-16 US US09/249,790 patent/US6344447B2/en not_active Expired - Lifetime
-
2003
- 2003-01-06 JP JP2003000721A patent/JP2003201240A/ja not_active Withdrawn
-
2009
- 2009-04-28 JP JP2009110077A patent/JP2009167213A/ja active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011500713A (ja) * | 2007-10-16 | 2011-01-06 | エイザイ インコーポレイテッド | シチジンデアミナーゼ阻害剤としての2’−フルオロ−2’−デオキシテトラヒドロウリジン |
JP2011513415A (ja) * | 2008-03-03 | 2011-04-28 | トスク インコーポレーティッド | 毒性を低減するためのメトトレキセートアジュバントおよびその使用法 |
US8853227B2 (en) | 2008-03-03 | 2014-10-07 | Tosk, Incorporated | Methotrexate adjuvants to reduce toxicity and methods for using the same |
US9382287B2 (en) | 2008-03-03 | 2016-07-05 | Tosk, Inc. | Methotrexate adjuvants to reduce toxicity and methods for using the same |
USRE48253E1 (en) | 2008-03-03 | 2020-10-13 | Tosk, Inc. | Methotrexate adjuvants to reduce toxicity and methods for using the same |
US11446303B2 (en) | 2019-06-21 | 2022-09-20 | Tosk, Inc. | Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions |
Also Published As
Publication number | Publication date |
---|---|
WO1996040165A1 (en) | 1996-12-19 |
HK1072897A1 (en) | 2005-09-16 |
KR19990022804A (ko) | 1999-03-25 |
DE69635941D1 (de) | 2006-05-11 |
US5968914A (en) | 1999-10-19 |
EP0831849A1 (en) | 1998-04-01 |
ATE320813T1 (de) | 2006-04-15 |
US6344447B2 (en) | 2002-02-05 |
DK1491201T3 (da) | 2006-07-31 |
AU724805B2 (en) | 2000-09-28 |
EP0831849A4 (en) | 2003-03-26 |
DE69635941T2 (de) | 2006-11-23 |
JP2003201240A (ja) | 2003-07-18 |
EP1491201A1 (en) | 2004-12-29 |
US20010025032A1 (en) | 2001-09-27 |
CN1192149A (zh) | 1998-09-02 |
EP1491201B1 (en) | 2006-03-22 |
PT1491201E (pt) | 2006-08-31 |
ES2257721T3 (es) | 2006-08-01 |
AU6111496A (en) | 1996-12-30 |
CA2223640A1 (en) | 1996-12-19 |
JP2009167213A (ja) | 2009-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10511689A (ja) | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤の毒性を減少させる方法 | |
US5736531A (en) | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides | |
JP2584947B2 (ja) | アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤毒性の治療 | |
WO1994026761A1 (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
US5691320A (en) | Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis | |
CA2193967C (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | |
JP2007332144A (ja) | 全身性炎症と炎症性肝炎の治療のためのピリミジンヌクレオチド前駆体 | |
US7776838B1 (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
US6329350B1 (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | |
AU2005232281A1 (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | |
AU5262499A (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | |
JPS6345372B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040316 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040304 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20040726 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040831 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050706 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050711 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20051129 |